Additionally, in ’09 2009 we identified a $10.2 million gain on the sale of a secured asset and incurred $4.0 million in restructuring charges. Net loss attributable to common shareholders was $147.6 million , in comparison to a net loss attributable to common shareholders of $116.8 million for the same period in ’09 2009. The upsurge in net loss attributable to common shareholders is principally due to a rise in noncash deemed dividends on desired stock linked to financing activities in 2010 2010.0 million in gross proceeds received from the Company’s equity financing in January 2011.. CTI’s fourth quarter net loss boosts to $34.1 million Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.The extensive research, led by Clas Johansson, PhD, a postdoctoral scholar in Blau’s laboratory, will be published on-line in Nature Cell Biology on April 20. The bone marrow-derived cells are known as blood stem cells, or hematopoietic stem cells. They can give rise to all of the bloodstream and immune cells in the physical body. Although the progeny of these hematopoietic stem cells possess previously been proven to fuse with a variety of other cell types in your body, this fusion occurs therefore infrequently that it had been thought to have little biological significance. Purkinje neurons are large cells in some of the mind referred to as the cerebellum, which is involved with motor and balance control. They type junctions between a great many other neurons, and they do not regenerate. They will be the only cell in the brain proven by Blau and others to fuse with these bone marrow-derived cells in mice and humans.